Share on StockTwits

Equities researchers at Wedbush hoisted their price objective on shares of United Therapeutics (NASDAQ:UTHR) from $119.00 to $133.00 in a research report issued on Thursday. Wedbush’s target price would indicate a potential upside of 42.57% from the stock’s previous close.

United Therapeutics (NASDAQ:UTHR) opened at 93.29 on Thursday. United Therapeutics has a 52 week low of $70.34 and a 52 week high of $116.65. The stock’s 50-day moving average is $91.14 and its 200-day moving average is $97.54. The company has a market cap of $4.494 billion and a price-to-earnings ratio of 21.34.

United Therapeutics (NASDAQ:UTHR) last released its earnings data on Tuesday, July 29th. The company reported $2.57 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter last year, the company posted $1.52 earnings per share. United Therapeutics’s revenue was up 15.0% compared to the same quarter last year. On average, analysts predict that United Therapeutics will post $7.96 earnings per share for the current fiscal year.

In other United Therapeutics news, COO Roger Jeffs sold 50,000 shares of United Therapeutics stock on the open market in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $96.25, for a total value of $4,812,500.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Several other analysts have also recently commented on the stock. Analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday. Separately, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday. They now have a “buy” rating on the stock. Finally, analysts at Credit Suisse raised their price target on shares of United Therapeutics from $75.00 to $100.00 in a research note on Wednesday. They now have a “neutral” rating on the stock. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company. United Therapeutics has an average rating of “Hold” and an average price target of $102.33.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.